Thu. 9 May 2024, 9:01am ET
Benzinga
Earnings, Earnings Beats, News
RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.81) by 2.47 percent. This is a 3.95 percent decrease over losses of $(0.76) per share from the same period last year.